Evidence map›Paper›PMID 25257482›Full record

ArticleStem cell research & therapy2014

Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats.

Xian-Bao Liu, Jian-An Wang, Xiao-Ya Ji, Shan Ping Yu, Ling Wei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xian-Bao Liu
Jian-An Wang
Xiao-Ya Ji
Shan Ping Yu
Ling Wei
Emory University · USSecond Affiliated Hospital of Zhejiang University · CN

Funding

Transplantation of Pre-conditioned Bone Marrow Mesenchymal Stem Cells after IscheR01NS062097 · NINDS · EMORY UNIVERSITY · PI WEI, LING · 2010 to 2014
$1.7M
Neuroprotection NR3A in Cultured Neurons and Ischemic NeonatesR01NS057255 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YU, SHAN P. · 2007 to 2011
$1.1M
Promoting axonal growth and tissue repair in stem cell therapy after strokeR21NS075338 · NINDS · EMORY UNIVERSITY · PI WEI, LING · 2011 to 2012
$426k
NINDS NIH HHS NS0458710NINDS NIH HHS NS057255NINDS NIH HHS NS062097NINDS NIH HHS NS075338NINDS NIH HHS R01 NS057255NINDS NIH HHS R01 NS062097NINDS NIH HHS R21 NS075338
6 · The paper itself

Abstract

introductionPoor cell survival and limited functional benefits have restricted the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of myocardial infarction. We showed recently that hypoxia preconditioning of BMSCs and neural progenitor cells before transplantation can enhance the survival and therapeutic properties of these cells in the ischemic brain and heart. The present investigation explores a novel strategy of preconditioning BMSCs using the Hypoxia-inducible factor 1α (HIF-α) prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG) to enhance their survival and therapeutic efficacy after transplantation into infarcted myocardium.

methodsBMSCs from green fluorescent protein transgenic rats were cultured with or without 1 mM DMOG for 24 hours in complete culture medium before transplantation. Survival and angiogenic factors were evaluated in vitro by trypan blue staining, Western blotting, and tube formation test. In an ischemic heart model of rats, BMSCs with and without DMOG preconditioning were intramyocardially transplanted into the peri-infarct region 30 minutes after permanent myocardial ischemia. Cell death was measured 24 hours after engraftment. Heart function, angiogenesis and infarct size were measured 4 weeks later.

resultsIn DMOG preconditioned BMSCs (DMOG-BMSCs), the expression of survival and angiogenic factors including HIF-1α, vascular endothelial growth factor, glucose transporter 1 and phospho-Akt were significantly increased. In comparison with control cells, DMOG-BMSCs showed higher viability and enhanced angiogenesis in both in vitro and in vivo assays. Transplantation of DMOG-BMSCs reduced heart infarct size and promoted functional benefits of the cell therapy.

conclusionsWe suggest that DMOG preconditioning enhances the survival capability of BMSCs and paracrine effects with increased differentiation potential. Prolyl hydroxylase inhibition is an effective and feasible strategy to enhance therapeutic efficacy and efficiency of BMSC transplantation therapy after heart ischemia.

Indexed as

Amino Acids, DicarboxylicAnimalsBone Marrow TransplantationCell DifferentiationCell SurvivalEchocardiographyIn Vitro TechniquesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMyocardial InfarctionNeovascularization, PhysiologicProlyl-Hydroxylase InhibitorsRandom AllocationRatsRats, TransgenicTransplantation ConditioningAmino Acids, DicarboxylicoxalylglycineProlyl-Hydroxylase Inhibitors

Identifiers

PMID25257482
PMCPMC4535299
OpenAlexW2110151008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.